Physician profile
Scott E Macdonald
NPI 1720482086
$5,308.41
in general payments reported to CMS, 2019-2025
25 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $786 · 2023: $1,032 · 2024: $1,185 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.07 |
| Education | $273.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.61 | 2021-2025 | |
| Janssen Biotech, INC. | $473.98 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $378.92 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $374.99 | 2021-2025 | |
| Lilly USA, LLC | $362.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $358.47 | 2021-2025 | |
| Galderma Laboratories, L.P. | $251.16 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $246.42 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $243.79 | 2023-2024 | Vtama |
| Pfizer INC. | $200.97 | 2021-2025 | |
| Genzyme Corporation | $192.29 | 2021-2025 | |
| Biofrontera INC. | $154.02 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $149.02 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $145.32 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $119.77 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.07 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $105.98 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $97.27 | 2021-2025 | Dupixent, Libtayo |
| Boston Scientific Corporation | $67.03 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $66.86 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.74 | 2021-2023 | Jublia |
| Organogenesis INC. | $31.07 | 2024 | Novachor |
| Strata Skin Sciences, INC. | $23.37 | 2025 | Xtrac |
| Springworks Therapeutics, INC. | $19.27 | 2025 | Gomekli |
| Journey Medical Corporation | $18.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.